

September 11, 2019

## Slides: Outlook for the US Economy

### Tariffs take us to the brink of recession

Seth Carpenter Chief US Economist Tel: +1-212-713 4173 seth.carpenter@ubs.com Robert Martin US Economist Tel: +1-212-713 2532 rob.martin@ubs.com

#### **Samuel Coffin**

US Economist Tel: +1-203-719 1252 <u>samuel.coffin@ubs.com</u> Laura Desplans US Economist Tel: +1-212-713 2513 laura.desplans@ubs.com Alan Detmeister US Economist Tel: +1-212-713 1222 alan.detmeister@ubs.com

This document has been prepared by UBS Securities LLC

#### ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON SLIDE 61

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

#### **Our Overview**

- Tariffs take us to the brink of recession
  - 2020H1 growth below 0.5%; unemployment rate rises to 4.3% by year end
  - Consumption dampened by job losses; investment is contracting
- The Fed shifts from "adjustment" to "easing cycle"
  - 25bp cut in September on fears
  - 100bps of cuts in 2020 on the deterioration of the data
- Inflation has accelerated, but there will be no breakout to the upside
  - April through July have had strong prints
  - Tariffs will temporarily boost inflation in 2020H1
  - The softer economy means inflation falls back going into 2021
- Balance sheet unwind has ended
  - Unwind ended in August; Fed is now buying Treasuries in the secondary market
  - Purchases along the curve. Expect future purchases to be more tilted to the front end
  - MBS prepayments have spiked on lower rates



## The Trade War drives our outlook

Ratcheting tariffs hit the economy



#### **Our Forecast**

September 9, 2019	2018		2019				2020				Q4/Q4			
	Q/Q % c	h, a.r.									% ch			
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	2018	2019	2020	2021
Real GDP	2.9	1.1	3.1	2.1	2.1	1.8	0.5	0.3	1.7	2.1	2.5	2.3	1.1	2.5
Personal consumption exp	3.5	1.4	1.1	4.3	2.5	1.7	0.9	0.7	1.6	1.9	2.6	2.4	1.3	2.1
Fixed investment	0.7	2.7	3.2	-0.8	0.4	0.7	-1.7	-1.4	2.0	2.9	3.5	0.9	0.4	6.1
Business fixed investment	2.1	4.8	4.4	-0.6	0.3	0.5	-2.3	-1.7	2.6	3.7	5.9	1.1	0.5	6.8
Structures	-2.1	-9.0	4.0	-10.6	-6.0	-3.2	-5.5	-4.8	1.0	2.0	2.6	-4.1	-1.9	6.8
Equipment	2.9	7.4	-0.1	0.7	0.0	-1.1	-3.8	-2.8	3.0	4.0	5.0	-0.1	0.0	6.8
Intellectual property products	4.1	11.7	10.8	4.7	4.7	4.7	1.5	1.5	3.2	4.5	9.3	6.2	2.7	6.8
Residential	-4.0	-4.7	-1.0	-1.5	1.0	1.5	0.5	0.0	0.0	-0.3	-4.4	0.0	0.1	3.6
Gov ernment purchases	2.1	-0.4	2.9	5.0	3.4	3.4	2.8	2.8	2.8	2.8	1.5	3.7	2.8	1.6
Net exports (contrib, pct pt)	-2.1	-0.4	0.7	-0.6	-0.3	-0.1	-0.2	-0.2	-0.2	-0.2	-0.4	-0.1	-0.2	-0.3
Exports	-6.2	1.5	4.1	-5.2	-2.3	-1.7	-8.8	-5.8	0.9	0.9	0.4	-1.3	-3.3	2.4
Imports	8.6	3.5	-1.5	0.1	0.0	-0.4	-5.5	-3.0	2.2	2.1	3.2	-0.5	-1.1	4.0
Inventory contribution (pct pts)	2.1	0.1	0.5	-0.9	0.0	0.0	-0.1	-0.2	0.0	0.0	0.3	-0.1	-0.1	0.0
Payrolls (monthly pace, 000s)	222	216	206	147	182	153	99	159	59	178	221	172	124	200
Private pay rolls	206	216	198	142	172	150	75	75	170	180	212	166	125	190
Civilian unemployment rate (%)	3.8	3.8	3.9	3.6	3.6	3.6	3.9	4.1	4.2	4.3	3.8	3.6	4.3	4.3
Labor force participation rate (%)	62.8	63.0	63.1	62.8	62.9	62.9	63.0	63.1	63.2	63.3	63.0	62.9	63.3	63.7
Inflation														
CPI-U	2.0	1.5	0.9	2.9	1.4	0.8	2.9	2.6	1.5	1.2	2.2	1.5	2.1	2.1
Core CPI-U	2.0	2.2	2.3	1.8	3.0	2.0	2.8	2.4	1.9	2.0	2.2	2.3	2.3	2.2
PCE Chain Price Index	1.6	1.3	0.4	2.3	1.6	1.1	2.6	2.4	1.4	1.1	1.9	1.4	1.9	1.8
Core PCE Chain Price Index	1.6	1.7	1.1	1.8	2.3	1.8	2.6	2.2	1.6	1.6	1.9	1.8	2.0	1.8
Income indicators														
Average hourly earnings	3.5	3.3	3.0	2.6	3.4	3.3	3.2	3.1	3.2	3.2	3.3	3.1	3.1	3.2
Employment cost index	3.0	2.7	3.0	2.4	2.9	2.9	2.9	3.0	3.1	3.1	2.9	2.8	3.0	3.2
Real disposable income	3.3	2.9	4.5	2.5	2.5	2.8	1.0	1.4	2.2	2.7	3.9	3.1	1.8	2.1
Saving rate (%)	7.5	7.8	8.5	8.0	8.0	8.3	8.3	8.4	8.6	8.7	7.8	8.3	8.7	8.7
Federal budget balance (\$ bil, FY)											-779	-991	-1052	-1019
Federal funds rate (top of range, %)	2.25	2.50	2.50	2.50	2.00	2.00	1.75	1.25	1.00	1.00	2.50	2.00	1.00	1.25

Source: Commerce Dep't, Federal Reserve, Bureau of Labor Statistics, Treasury Department, & UBS



#### We are more than 18 months into this trade war

Repeated tariff actions leave the US economy vulnerable and reeling

### Major trade actions will bring total value of imports under tariff to \$551bln by year end

Tariffed item	Country	Date	Rate	2017 blns
Washing machines	Global	7-Feb-2018	20%	1.7
Solar panels	Global	7-Feb-2018	30%	7.3
Steel	Global	1-Mar-2018	25%	9
Aluminum	Global	1-Mar-2018	10%	13
Tranche 1 \$34bln	China	6-Jul-18	25%	34
Tranche 2 \$16bln	China	23-Aug-2018	25%	16
Tranche 3 \$200bln	China	24-Sep-18	10%	200
Tranche 3 \$200bln	China	10-May-2019	25%	200
Tranche 4 \$113bln	China	1-Sep-19	15%	113
Tranche 1-3 \$250bln	China	1-Oct-2019	30%	250
Tranche 5 \$157bln	China	15-Dec-19	15%	157
Total		weighted	22%	551
Already in effect		weighted	22%	363


#### About 22% of US imports are under new tariffs

\* The 22% for imports, 22% weighted tariffs on 551, and 22% weighted tariffs on 363 are a coincidence and are correct

Source: UBS, USTR



### Through September 1, new 2019 trade actions have double notional effective size of tariffs\*\*



### By December, notional tariffs will be three times their 2018 size


5% increments feel small but add up when applied to large numbers

\*\* Notional effective size does not equal tariffs collected at border as volumes have changed since tariff implementation. The black line is the sum of the rate times the billions in the table.

### Imports of goods under tariff have fallen

First tranche (\$34bn): US imports down about 40% post tariffs

Tariff elasticities are much larger than previously believed



Second tranche (\$16bn): US imports down about 40% post tariffs


Source: US Census, UBS

Source: US Census, UBS




# Tariffed imports from China have fallen 40% on 13% average weighted tariffs, an elasticity about 3 times larger than that assumed by Federal Reserve models

Third tranche (\$200bn): US imports from China have fallen about 40% since tariffs hit in Sept.



Tariffed imports from China in first tranches are down 40%; in Q2, imports lost from China began to arrive from other countries but that effect has now faded




Source: US Census, UBS


### The decline in trade led to a decline in US activity

The inability to withstand higher taxes led to shuttered production lines (and layoffs)

The tariffs induced a pothole in domestic demand and a rise in the unemployment rate



The rise in the unemployment rate was mirrored (driven) by a rise in initial claims; claims have been elevated relative to trend for about 10 months




Note: PDFP is private domestic demand. U3 is unemployment Source: US Census, UBS

Source: BLS, UBS

### Tariffs hurt hiring and weak hiring hurt consumption


Household consumption is sensitive to employment prospects

The job finding rate began to fall as soon as tariffs were first implemented; it surged in late Q1 as firms began to find alternative sources of supply



Probability of dropping benefits before exhaustion

Note: The job-finding rate is the probability of finding new employment before benefit exhaustion after filling an initial claim. Manufacturing states: MN, WI, IL, IN, OH, MO, MO, KY, TN AL, GA, FL. Source: DOL, UBS The economic impact of tariffs extended to consumption, which hit a pothole from Dec to Feb and recovered in March as job finding rate jumped higher







## Focus on the near-term forecast


We see GDP at a near standstill in early 2020




### Renewed tariffs: renewed slump in activity

We see an ordinary near-recession slowdown in Q1 and Q2

GDP and consumption growth slow to a near standstill in early 2020; risks are skewed to the downside through Q2 2020



With new tariff already announced, investment never finds its footing and declines a lot in Q1 and Q2 as general malaise intensifies




Source: BEA, UBS

Source: BEA, UBS


#### Risks are to the downside as employment has already slowed

A weak economy has less ability to endure new shocks

Employment growth remains steady until just before US recessions; few soft landings



We estimate that after the benchmark revisions are incorporated employment will show an even stronger slowing pattern



Source: UBS, BLS


Note: We know that the BLS will subtract 514k from the level of March 2019 private employment. We do not yet know to which months the BLS will allocate those revisions. Source: BLS, UBS


Star UBS

#### We have not run out of workers – firms just slowed hiring

Extent of untapped labor supply remains unclear but is likely substantial

Prime-age employment/population is far below the peaks of the last two expansions; the gap with 1990s is 8.8m or 44 months of 200k job gains Prime-age participation fell sharply but has moved higher for 4 years; younger women have re-entered and male participation stabilized





Source: UBS, BLS


Source: UBS, BLS




### Risks are to the downside as employment has already slowed

A weak economy has less ability to endure new shocks

Manufacturing and retail employment are especially vulnerable under the new tariffs; the two sectors are already reeling



### Consistent with weakness in manufacturing, core capital goods shipment growth has stalled



Source: UBS, BLS

Source: Census, UBS


### Cheap oil is a big risk; Lower demand will slow production

Following large positive contributions, energy likely subtracting from growth now

### The world is consuming increasing amounts of US oil; the oil balance is closing




### The balance has shifted and the US is now more sensitive to downside oil than up




Source: UBS, Baker Hughes

### Housing has been tepid for several years

But does not pose an independent risk to the outlook



## We expect starts to move lower with the weakness in activity New home sales show current strength as rates have fallen and as early-year weakness was overstated




Source: NAR, Census, UBS


#### Auto sales have stabilized

We expect slowing in early 2020

#### Auto sales seem to have stabilized around 17mln; we expect a low-water mark of about 16mln in H1 2020



### The mean age of light cars is approaching 12 years; will likely increase if sales slump




Source: UBS, US Census For more detail see <u>Auto Aftermarket: A View from the investment community</u>


Source: UBS, BEA

#### The number of repair establishments is rising

Size per establishment increased but the industry remains massively fragmented








Source: : IbisWorld, UBS For more detail see <u>Auto Aftermarket: A View from the investment community</u>

Source: UBS, Census




## The Fed

### 4 cuts in 2020 following 2 cuts in 2019




#### The Fed cuts rates semi-aggressive in response to slowing

Does not adjust balance sheet policy from here








### Inflation is likely to be well below target this year

With unemployment rate below NAIRU, the FOMC will expect inflation to rise to target

### The FOMC's long-run unemployment rate forecast tends to follow the data



# The longer-run dot fell to 2.5% in June. It has drifted notably lower since 2012, essentially following market interest rates




Source: UBS, Bloomberg, Federal Reserve

Back in June, prior to the recent trade war escalation, the Committee saw real GDP growth at 2.1% this year


	Median					
	2019	2020	2021	Longer run		
Change in real GDP	2.1	2.0	1.8	1.9		
Mar. projection	2.1	1.9	1.8	1.9		
Unemployment rate	3.6	3.7	3.8	4.2		
Mar. projection	3.7	3.8	3.9	4.3		
PCE inflation	1.5	1.9	2.0	2.0		
Mar. projection	1.8	2.0	2.0	2.0		
Core PCE inflation	1.8	1.9	2.0			
Mar. projection	2.0	2.0	2.0			
Federal funds rate	2.4	2.1	2.4	2.5		
Mar. projection	2.4	2.6	2.6	2.8		

Source: UBS, Federal Reserve

#### FOMC sees core inflation hitting 1.8% in 2019




Source: UBS, BEA, Federal Reserve



#### A mass of the dots shifted downward at the June meeting

### Inversion of the yield curve has not always tightly predicted cuts in the past



Source: UBS, Federal Reserve

Source: UBS, Federal Reserve

#### Unwind ended in August; Fed is now buying Treasuries in the secondary market

MBS continue to runoff, Fed is buying Treasuries to replace them

Reserves will likely continue to decline until next year; we expect \$1.2 trillion

To hold reserves constant, the Fed will have to buy \$20 billion or more in Treasuries each month


	Aug 8, 2007	Sep 2017	Aug 2019	Mar 2020*
	Pre-crisis	Pre-runoff	Latest data	
Total Assets	0.9	4.5	3.8	3.8
Treasuries	0.8	2.5	2.1	2.2
MBS	-	1.8	1.5	1.4
Other	-	0.2	0.2	0.2
Total Liabilities	0.8	4.4	3.7	3.8
Currency	0.8	1.5	1.7	1.8
Reserves	-	2.2	1.5	1.2
Reverse Repurchase Agreements	-	0.5	0.3	0.3
Treasury General Account	-	0.2	0.2	0.4
Other	-	-	-	-
Capital	-	-	-	-

Note: US\$ trillions. \*Projection. Source: UBS, FRB



#### Currency and nominal GDP don't grow at the same rate


Currency has been growing close to 7% annually



Source: UBS, FRB, BEA


#### The Fed's balance sheet hits a low of \$3.8 trillion then rises again

Currency growth drives the balance sheet after mid-2020 (as it has always done)



Reserves and currency

Currency grows at the slowest pace we could envision



Source: UBS, FRB




Inflation Running below target




#### Tariffs have slightly boosted core inflation; oil has held down headline

With the hit to activity from tariffs, inflation settles below the Fed's target (once again) in 2021; tariffs raise prices not inflation



### Core goods inflation jumps higher with tariffs before returning to negative territory




Source: UBS, BLS

Source: UBS, BLS




#### Wage inflation accelerated over the past two years

We expect stability at about 3% over next two



#### Hourly compensation



Source: UBS, BLS

Source: UBS, BLS

#### The impact of the tariffs on inflation is expected to be temporary

Most of the effect of the tariffs implemented in 2018 has likely already passed through

#### Estimated effect of tariffs on consumer prices

Tariffed item	Countries affected	Starting date	Size of tariff	\$ imports (billions)	Pass- through rate	Core PCE priœ effect
2018 tariffs:						
Washing machines	Global	7-Feb-2018	20%	1.7	65%	0.002%
Solar panels	Global	7-Feb-2018	30%	7.3	65%	0.011%
Steel	Global w excp	1-Mar-2018	25%	9	65%	0.011%
Aluminum	Global w excp	1-Mar-2018	10%	13	65%	0.007%
Initial tranches of imports from China (tranche 1 and 2)	China	\$34b 6-Jul-18; \$16b 23-Aug-18	25%	50	13%	0.013%
\$200b of imports from China to 10% (tranche 3)	China	24-Sep-2018	10%	200	29%	0.044%
Estimated effect of tariffs implemented in 2018				381		0.09%
2019 tariffs in our baseline:						
\$200b of imports from China from 10% to 25%	China	10-May-2019	+15%	200	29%	0.066%
China tranche 4A	China	1-Sep-2019	15%	113	45%	0.058%
Additional 5% on tranches 1, 2, & 3	China	1-Oct-2019	+5%	250	26%	0.025%
China tranche 4B	China	15-Dec-2019	15%	157	84%	0.152%
Total of 2018 and 2019 tariffs						0.39%

Note: CPI effect calculated as size of tariff\*pass-through rate\*\$ value of imports/\$value of US GDP. Pass-through rate roughly based on share of imports coming from China. Source: UBS



#### Inflation is low y/y but rising in the recent data

Core goods inflation has increased significantly since 2017

### Core goods have risen on tariffs and consumer import prices (ex tariffs) have eased recently

Percent, y/y 1.0 0.5 0.0 -0.5 -1.0 -1.5 13 16 18 19 15 14 17 Consumer import prices (ex autos) •Core CPI goods Core inflation has fallen this year, but is still above 2017 levels


	2017	2018	Jul-19	2019*	2020*	2021*
			12-montl	n change		
Headline	2.1	1.9	1.8	1.8	2.0	2.0
Food	1.6	1.6	1.8			
Energy	6.9	-0.3	-2.0			
Core CPI	1.8	2.2	2.2	2.3	2.2	2.2
Core Services	2.6	2.9	2.8	2.9	2.9	3.1
OFR	3.2	3.2	3.4			
Rent	3.7	3.5	3.8			
Lodging	0.6	0.7	4.6			
Medical care	1.6	2.6	3.3			
Airline	-4.0	-2.6	1.3			
Educ & comm	-1.7	0.2	0.6			
Core goods	-0.7	0.1	0.4	0.6	0.0	-0.6
Apparel	-1.6	-0.1	-0.5			
New vehicles	-0.5	-0.3	0.3			
Used Vehicles	-1.0	1.4	1.5			
Medical care	2.3	-0.5	-0.4			

Note: Yearly numbers are Dec over Dec. \*Forecast. Source: UBS, BLS


Source: UBS, BLS

#### Medical services prices remain low compared to the previous expansion

CPI medical services inflation has been rising, while PCE healthcare service inflation has slowed



Medical care commodities inflation slowed last year




Source: UBS, BLS, BEA


Source: UBS, US Census

#### Some measures of long-run inflation expectations have eased

#### Inflation expectations of consumers and businesses have dipped since December



#### Long-term PCE expectations remain at the FOMC objective, but CPI expectations have slipped




Source: UBS, Michigan SRC, Atlanta Fed, New York Fed

Source: UBS, Philadelphia Fed


#### **Rising rents push overall inflation higher**

Rents are 40% of core CPI basket (18% of core PCE)

We expect housing rents to move up a little less than 4% per year amid low unemployment and continued low vacancy rates




#### Both rents and OER have slowed slightly since early 2017




Source: UBS, BLS

#### Vacancy rates remain low; household formation recovering

### The low vacancy rate should put upward pressure on rents, house prices, and starts



### Household formation had stabilized but shows some hints of recent softness



Source: UBS, US Census

Source: UBS, US Census




## Supporting charts




# The expansion of manufacturing and the consolidation of the retail sector both play substantive rolls in our outlook

The US experienced a surge of new manufacturing establishments in 2017-18; the strongest gains since the 90s; these establishments are especially vulnerable to tariff shocks




## Consumers continue to shift purchases towards online only outlets; this shift is disruptive to traditional retailers



Source: UBS, BLS

Source: UBS, US Census

### The unemployment outlook has improved substantially in industrial states




Source: UBS Evidence Lab, UBS, Census




## Tariffed goods drive trade weakness

### Excluding China trade volumes continue to expand

## Real imports and exports have been moving roughly sideways since mid-2018




## Exports from non-Chinese, EM Asian sources continue to rise at about their pre-tariff pace




Source: Haver Analytics, UBS

Source: US Census, UBS

## Fourth tranche (\$300bn): US imports from China have not fallen so far




## No evidence that Vietnam is a transshipping hub for tariffed goods



Source: US Census, UBS

## Tariffs on the \$200bn tranche increased to 25% in May

Tariffs of 10% will be implemented on the \$300bn tranche in Sept and Dec




Source: US Census, UBS

**Retaliation to first tranche:** US exports down sharply (though decline started before tariffs)

**Retaliation to second tranche:** US exports down significantly; acceleration pre-tariff was too early to be just front-running

**Retaliation to third tranche:** Hit peak well before tariffs. Weakness: both tariff effects and pre-existing weakness in Chinese demand



Billions

8.0

7.5

7.0

6.5


6.0

5.5


5.0

19

#### Shipments of soy to non-traditional fall buyers increased as China demand fell to zero



## Exports of other ag products have trended lower but are still substantial



#### Source: US Census, UBS

#### Source: US Census, UBS

Note: US farmers continue to face outsized tariff headwinds; but, they have managed to find alternative sources of demand for some product s. While shipments of soy to China were near zero last fall, exports of soy to the rest of the world were elevated, much as we expected shortly after tariffs were announced (Link). We also note that, while purchases are not sufficient to make up for lost volumes last fall, exports to China in 2019 are very large for time of year. The US has shipped soy to China at a pace just below 0.5bln per month, well above the zero shipments typically observed in the first few months of the year.



### Manufacturing sentiment has been weakening



30

20

10

0


-10

-20

### A case study on washing machines

Our macro forecast is guided, in part, by the response of washing machines to tariffs

## Washing machine imports soared pre-tariff, as manufacturers knew tariffs were coming



## Prices of laundry equipment, washing machines and dryers, jumped 20% post-tariff, retracing





Source: UBS, BLS

### A case study on washing machines

Our macro forecast is guided, in part, by the response of washing machines to tariffs


Tariffs on Chinese washing machines led to an immediate substitution to Vietnamese imports





### Mapping energy into the national economy

Everything in picture is energy-related; nothing is counted as such in national accounts




Source: Google maps -- 14207 U.S. 2, Williston, ND 58801

, UBS Note: 1, hotel construction; 2, oil rig assembled but not active; 3, construction machinery; 4, heavy duty trucks; 5, light trucks; 6, machinery shop; 7, pumps for oil but not active; 8, rig pieces ready to be assembled.



### The initial rise in capital goods shipments was driven by energy

We have seen a rise in non-energy shipments driven by manufacturing



Note: Potentially commodity driven categories include primary metals, fabricated metal products, construction machinery, mining, oil, and gas field machinery, industrial machinery, ventilation, heating & air conditioning, metalworking machinery, turbines and other power generating machinery, heavy duty trucks, petroleum and coal products, electric equip excluding appliances, batteries, and electric lighting.

Source: UBS, US Census





### **Energy output continues to rise**

### But we have growing concerns over the health of the sector

## Petroleum production is surging; Permian may hit supply constraints but not yet

Inventories of oil are falling again






Source: UBS, EIA

Source: UBS, EIA




## **Consumer balance sheets look broadly healthy**

Households appear in good shape to weather a temporary growth slowdown



HH liabilities are falling as a percentage of income and net

## Assets had been rising healthily as a share of income but took a hit in Q4




Source: Federal Reserve, BEA, UBS

worth


## **Consumer balance sheets look broadly healthy**


Households appear in good shape to weather a temporary growth slowdown



Debt service levels remain low despite interest rate

#### Delinquency rates on cards and auto moved higher






Source: Federal Reserve, UBS

increases


### Housing remains weak



Most households think it is a better time to sell than buy, which has preceded the past two recessions


#### Source: NAR, Census, UBS

#### But housing a much smaller share of GDP



Source: BEA, UBS

#### ... and household formation is rising




Source: Census, UBS


### **Employment growth is a key indicator for the US**

Employment growth tends to remain steady until just

before US recessions; no soft landings



#### **Employment growth is slowing**





Source: UBS, BLS

Source: UBS, BLS




### Survey measures continue to be indicative of increasing wage growth





Source: NFIB, UBS

#### **NFIB and Conference Board tightness**




Source: NFIB, Conference Board, UBS

#### NABE wage growth



Source: UBS, NABE


#### **Duke/CFO Magazine Outlook**



Source: UBS, Duke/CFO Magazine

### The Fed's balance sheet has changed dramatically since the crisis

It used to be liability driven; post-crisis, it's been asset driven



Source: UBS, Federal Reserve


Source: UBS, Federal Reserve



### The discussion of monetary frameworks will take time


Inflation averaging is popular, but the devil is in the details

## Core and headline inflation have persistently undershot the Fed's target, despite the decline in the unemployment rate




Source: BEA, UBS

The seasonality in sentiment seems to be related to seasonality in core PCE inflation; PCE tends to underperform late in the year and outperform early




## The FOMC is worried that persistent shortfalls of inflation are lowering inflation expectations



Source: University of Michigan, UBS

Correcting 10 years of persistent inflation undershoots requires substantial overshoots of the target, even assuming an instant shift in inflation




Source: BEA, UBS

## A sharp, nonlinear pickup in inflation is an upside risk if the unemployment rate

### continues falling

Metropolitan data over the last 20 years shows only moderate nonlinearity, and we have brought that into our baseline

The 1960s experience suggests a much larger upside risk



Source: UBS based on Babb and Detmeister (2017)

Source: UBS, BLS



## **Treasury issuance**

## Coupon issuance should remain unchanged this year



## Coupon issuance should remain unchanged in 2019

Given current auction sizes, our deficit forecast and the fact that the Fed is fully reinvesting maturing securities, the Treasury should be fairly well funded

With bills outstanding quite low as a share of issuance, an upside surprise to funding needs would bring little need to adjust coupons

We expect auction sizes to remain unchanged in 2020 too


		2у	3у	5у	7у	10y	30y	FRNs (2y)	5y TIPS	10y TIPS	30y TIPS	Total to market	Total maturing to market	Net market takedow n	Total maturing	Fed balance sheet rolloff	SOM A add-ons	(1) Fed purchases in secondary markets	(1.a ) Purchases due to MBS reinvestments	(1.b) Purchases due to currency grow th
*	Jan-19	40	38	41	32	24	16	20	0	13	0	224	161	63	177	16	0	0	0	0
*	Feb-19	40	38	41	32	27	19	18	0	0	8	223	136	87	192	30	26	0	0	0
*	Mar-19	40	38	41	32	24	16	18	0	11	0	220	2	218	24	22	0	0	0	0
*	Apr-19	40	38	41	32	24	16	20	17	0	0	228	279	-51	311	30	2	0	0	0
*	May-19	40	38	41	32	27	19	18	0	11	0	226	128	98	187	15	44	0	0	0
*	Jun-19	40	38	41	32	24	16	18	15	0	0	224	3	221	24	21	0	0	0	0
*	Jul-19	40	38	41	32	24	16	20	0	14	0	225	251	-26	272	8	13	0	0	0
	Aug-19	40	38	41	32	27	19	18	0	0	6	221	57	164	112	0	55	8	8	0
	Sep-19	40	38	41	32	24	16	18	0	12	0	221	180	41	208	0	28	8	8	0
	Oct-19	40	38	41	32	24	16	20	17	0	0	228	140	88	156	0	16	8	8	0
	Nov-19	40	38	41	32	27	19	18	0	12	0	227	61	166	100	0	40	8	8	0
	Dec-19	40	38	41	32	24	16	18	15	0	0	224	190	34	209	0	19	8	8	0
	Total	480	456	492	384	300	204	224	64	73	14	2,691	1,587	1,104	1,972	143	241	39	39	0

Note: \*Actual. Source: US Treasury, UBS

### Bills as a % of marketable debt to stay low before moving higher

Bills as a % of marketable debt is below the historical

With earlier end to balance sheet unwind, Treasury will see need for modestly smaller bills auction sizes



## The average maturity outstanding marketable debt has

## The UBS US Economics Team

<u>Seth Carpenter</u> – Chief US Economist with specialty in Fed policy, Fed and Treasury balance sheets and financial markets. Ph.D. Economics Princeton; Former head of US Research at Rokos; Former Assistant Secretary for Financial Markets and Deputy Assistant Secretary for Macroeconomic Analysis at US Department of the Treasury; Former Deputy Director of Division of Monetary Affairs at Federal Reserve Board; 15-year Fed veteran. <u>seth.carpenter@ubs.com</u>; 1-212-713 4173

<u>Rob Martin</u> – US Economist with specialties in all things macro but always uses a micro lens. He served 13 years at the Fed in DC. He ran the Fed's international capital markets sections. He served one year in the CEA in the Bush White House, where amongst other topics he worked on trade policy. He taught at the University of Chicago, Johns Hopkins, and Georgetown. He received his Ph.D. from the University of Chicago. Two Nobel laureates served on his committee: Hansen and Lucas. He was a paratrooper in the 82nd Airborne Division. <u>rob.martin@ubs.com</u>; 1-212-713 2532

<u>Alan Detmeister</u> – Senior US Economist with specialty in price and wage inflation; Ph.D. Economics UC Berkeley; Former Chief of Federal Reserve Board's Prices and Wages section; 15-year Fed veteran; Former US and Iceland desk economist at OECD. <u>alan.detmeister@ubs.com</u>; 1-212-713 1222

<u>Sam Coffin</u> – Senior US Economist with specialty in high frequency incoming data and GDP projection; with UBS since November 2000, and prior to that PaineWebber, the Federal Reserve Board, and the World Bank. <u>samuel.coffin@ubs.com</u>; 1-203-719 1252

Laura Desplans – US Economist with specialty in econometrics and forecasting; also responsible for Canada. She earned her Ph.D. in Economics from the University of Rochester. Prior to joining UBS, she served two years as a US Economist and US Rates and Inflation Strategist at Deutsche Bank. She also spent brief stints at the IMF, the Federal Reserve Bank of St. Louis, and the Bank of Spain. <u>laura.desplans@ubs.com</u>; 1-212-713 2513

## **WBS**

## **Required Disclosures**

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit <u>www.ubs.com/disclosures</u>. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 11 September 2019 11:39 AM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those department members publish research principally on the analysis of the price or market for a derivative, and provide information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst is responsible for the derivatives investment views, forecasts, and/or recommendations.

## **Analyst Certification**

#### **Analyst Certification**

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## **Global Disclaimer**

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

This Document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately destroy the Document.

Global Research is provided to our clients through UBS Neo, and in certain instances, UBS com and any other system or distribution method specifically identified in one or more communications distributed through UBS Neo or UBS com (each a system) as an approved means for distributing Global Research. It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo Patform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the Neo Terms and where applicable the UBS Investment Bank terms of business (http://www.ubs.com/global/en/logalinfo2/disclaimer.html). In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (http://www.ubs.com/global/en/logale/en/loga

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction.

This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise. Constitutes a personal recommendation. By providing this document, none of UES or its representatives has any responsibility or authority to provide or have provide investment advice in a fiduciary capacity or otherwise. Investments involve risks, and investor's should exercise prudence and their own, the recipient or any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors.

Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <a href="http://www.theocc.com/publications/risks/riskchap1.jsp">http://www.theocc.com/publications/risks/riskchap1.jsp</a> or ask your salesperson for a copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons, recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options transactions.

Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, dients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and circumstances of his or her investment objectives.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS s internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or other representative of UBS. Any statements contained in this report attributed to a third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount (" Values" )) be used for any of the following purposes:

(i) valuation or accounting purposes;

(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or

(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of defining the asset allocation of portfolio or of computing performance fees.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit <u>www.ubs.com/disclosures</u>.

Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS and/or its divisions as a whole, of which investment banking, sales and triading are a part, and UBSs subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is expanded in this document. For financial instruments of the regulated market: UBS may act as a market maker or liquidity provider is user save that where the activity of liquidity provider is separated of in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the definition given to it by the relevant laws and regulations, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker or incord in the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiHD II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.

Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab you understand that UBS Evidence Lab is a separate department to Global Research and that UBS Evidence Lab does not provide research, investment recommendations or advice.



## **Global Disclaimer (Continued)**

United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Europe: Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible counterparties or professional dients (as detailed in the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin)Rules and according to MIRD) and are only available to such persons. The information does not apply to, and should not be relied upon by, retail dients. UBS Europe SE is authorised by the [European Central Bank (ECB)] and regulated by the BaFin and the ECB. France: Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities France S.A. UBS Securities France S.A. ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France SA. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. Germany, Luxembourg, the Netherlands, Belgium and Ireland: Prepared by UBS AG, London Branch and distributed by UBS AG, London Branch and UBS Europe SE. Spain: Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. Poland: Distributed by UBS Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE (soolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE (soolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. Russia: Prepared and distributed by UBS Bank (OOO). Switzerland: Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). Italy: Prepared by UBS Europe SE and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE, Italy Branch. Distributed by UBS South Africa (Ry) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). Israel: This material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS AG, London Branch is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. being issued only to and/or is directed only at persons who are Higible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons. Saudi Arabia: This document has been issued by UBSAG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. UAE / Dubai: The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE Securities and Commodities Authority. United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a 'non-US affiliate') to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule. Canada: Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. Mexico: This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V. and S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V. and S.A. de C.V. and is a subsidiary of UBS Casa de Bolsa, S.A. de C.V. and S document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please go to www.ubs.com/disclosures, Brazil: Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM SA. to persons who are eligible investors residing in Brazil, which are considered to be Investidores Profissionais, as designated by the applicable regulation, mainly the CVM Instruction No. 539 from the 13th of November 2013 (determines the duty to verify the suitability of products, services and transactions with regards to the client's profile). Hong Kong: Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch, which is incorporated in Switzerland with limited liability. Please contact local licensed/registered representatives of UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch in respect of any matters arising from, or in connection with, the analysis or document. Singapore: Distributed by UBS Securities Re. Ltd. [MCI (P) 009/09/2018 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Rease contact UBS Securities Re. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branch, and a single bank licensed under the Singapore Branc Monetary Authority of Sngapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). Japan: Distributed by UBS Securities Japan Co., Ltd., to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant. Australia: Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No. 231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecsresearch-fsq. New Zealand: Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a "wholesale client" within the meaning of section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related entities (and their respective Directors, officers, agents and Advisors) (each a 'Relevant Person') for any loss, damage, liability or claim any of them may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication or material. Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients. India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Number: INZ000259830; merchant banking services bearing services bearing services bearing services bearing services bearing INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: al/en/about ubs/investor relations/annualreporting.html. Taiwan: Distributed by UBS Securities Re. Ltd., Taipei Branch which is regulated by the Taiwan Securities and Futures Bureau. This document contains general information and/or general advice only and does NOT constitute any "Recommendation" to clients for the covered companies or any companies mentioned in this document. Indonesia: This report is being distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having its registered office at Wisma GKBI, 22nd floor, L Jend. Sudirman, kav.28, Jakarta 10210, Indonesia, is a subsidiary company of UBS AG and licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK). Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.

The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS All rights respect.



UBS Securities LLC 1285 Avenue of the Americas New York, NY 10019

Tel: +1-212-713-2000

www.ubs.com

